Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy

Neoplasma

Volumn 50, Issue 3, 2003, Pages 204-209

  Juan, O ^a   Albert, A ^a   Villarroya, T ^a   Sanchez R ^a   Casan, R ^a   Caranana, V ^a   Campos, J M ^a   Alberola, V ^a  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Co morbidities; Non cisplatin therapy; Non small cell lung cancer; Second line therapy; Weekly paclitaxel

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DEXCHLORPHENIRAMINE; PACLITAXEL; PLATINUM; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COMORBIDITY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG TOLERABILITY; DYSPNEA; ELDERLY CARE; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; PROGNOSIS; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0038269607     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. AKERLEY W, CHOY H, SAFRAN H, SIKOV W, REGE V, SANMANDAM S, WITTELS E. Weekly paclitaxel in patients with advanced lung cancer: Preliminary date from a phase II trial. Semin Oncol 1997; 4 suppl 12: S12-10-S12-13.
2. AKERLEY W, GLANTZ M, CHOY H, REGE V, SANWANDAM S, JOSEPH P. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16:153-158.
3. DEVORE III RF, JAGASIA M, JOHNSON DH. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: Preliminary results comparing sequential phase II trials. Semin Oncol 1997; 24 suppl. 12: S12-27-S12-29.
4. DU BOIS A, SCHLAICH M, LUCK L, MOLLENKOPF A, WECHSEL U, RAUCHHOLZ M, BAUKNECHT T, MEERPOHL H. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Support Care Cancer 1999; 7: 354-361.
5. FERRIGNO D, BUCCHERI G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a diference? Lung Cancer 2000; 29: 91-104.
6. FIDIAS P, SUPKO JG, MARTINS R, BORAL A, CAREY R, GROSSBARD M, SHAPIRO G, OSTLER P, LUCCA J, JOHNSON BE, SKARINS A, LYNCH TJ. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7: 3942-3949.
7. FOSSELLA FV, DEVORE R, KERR RN, CRAWFORD J, NATALE RR, DUNPHY F, KALMAN L, MILLER V, LEE JS, MOORE M, GANDARA D, KARP D, VOKES E, KRIS M, KAM Y, GAMZA F, HAMMERSHAIMB L, and the TAX 320 Non-Small-Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbina or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
8. FRY WA, MENCK HR, WINCHESTER DP. The National Cancer Data Base report on lung cancer. Cancer 1996; 77: 1947-1955.
9. GOGAS H, SHAPIRO F, AGHAJANIAN C, FENNELLY D, ALMADRONES L, HOSKINS WJ, SPRIGGS DR. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 1996; 61: 22-28.
10. GRIDELLI C. Chemotherapy of advanced non-small cell lung cancer in the elderly: an update. Crit Rev Oncol Hematol 2000;35:219-225.
11. HAINSWORTH JD, BURRIS HA, LITCHY S, MORRISSEY LH, BARTON JH, BRADOF JE, GRECO FA. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89: 328-333.
12. HOTTON KM, KIM K, McGOVERN J, LARSON ML, HAMMES LC, SCHILLER JH. Preliminary results of two phase II studies of weekly paclitaxel in patients (Pts) with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000 (abstr 2103); 18: 534.
13. HUISMAN C, SMIT EF, GIACONE G, POSTMUS PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000; 18: 3722-3730.
14. KIES M, UNGER P, GILLENWATER HH, SMITH S, PETERMAN A, SCHELL M, SOCINSKI M. Second-line (SL) weekly paclitaxel (P) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) failing first-line carboplatin/paclitaxel (C/P). Proc Am Soc Clin Oncol 2000 (abst 1971); 19:504.
15. KLAASSEN U, WILKE H, STRUMBERG D, EBERHARDT W, KORN M, SEEBER S. Phase I study a weekly 1h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996; 32A: 547-549.
16. LOPES NM, ADAMS EF, PITTS TW, BHUYAN BK. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235-242.
17. MARINO P, PAMPALLONA S, PREATONI A, CANTONI A, INVERNIZZI F. Chemotherapy versus supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
18. NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
19. PACE A, BOVE L, ALOE A, NARDI M, PIETRANGELI A, CALABRESI F, INNOCENTI P, JANDOLO B. Paclitaxel neuro-toxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 1997; 18: 73-79.
20. SCHIFF PB, FANT J, HORWITZ SB. Promotion of microtubule assembly by Taxol. Nature 1979; 277: 655-667.
21. SEIDMAN AD, HUDIS CA, ALBANEL J, TONG W, TEPLER I, CURRIE V, MOYNAHAN ME, THEODOULOU M, GOLLUB M, BASELGA J, NORTON L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-3361.
22. SHEPHERD FA, DANCEY J, RAMLAU R, MATTSON K, GRALLA R, O'ROURKE M, LEVITAN N, GRESSOT L, VINCENT M, BURKES R, COUGHLIN S, KIM Y, BERILLE J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 2000; 18: 1095-2103.
23. SOCINSKI MA, LANGER CJ. Single agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. Semin Oncol 1999; 26 suppl 16:51-61.
24. SOCINSKI MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. The Oncologist 1999; 4: 408-416.
25. SOCINSKY MA, MICHAEL JS, BAKRI K, PETERMAN A, LEE J, UNGER P, YATES S, HUDGENS S, KIES MS. Second-line, low-dose. Weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer 2002; 95: 1065-1073.
26. SOLA C, LLUCH A, GARCIA-CONDE J, OJEDA B, HORNEDO J, BENAVIDES M, SOLANO C, GARCIA T, SALAZAR R, ALONSO S, CORTESFUNES H, LOPEZ JJ. Phase II study of weekly paclitaxel (P) in recurrent breast cancer after high-dose chemotherapy (HDC). Proc Am Soc Clin Oncol 1998 (abstr 669); 17: 174.
27. SOUQUET PJ, CHAUVIN F, BOISSEL JP, CELLERELLO R, CORMIER Y, GANZ PA, KAASA S, PATER JL, QUOIX E, RAPP E, TUMARELLO D, WILLIAMS J, WOODS BL, BERNARD JP. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.